Table 1.

Types of checkpoint inhibitors and targeted cancers.

Class of ICI	Drug	Types of targeted cancers
CTLA-4-i	Ipilimumab	Melanoma
PD1-i	Nivolumab	Melanoma, NSCLC, SLCL, RCC, HCC, Hodgkin's lymphoma, head and neck cancer, metastatic colorectal cancer, urothelial carcinoma
	Pembrolizumab	Melanoma, NSCLC, Hodgkin's lymphoma, urothelial carcinoma, gastric cancer, large B cell lymphoma primarily mediastinal location, cervical cancer
	Cemiplimab	Metastatic cutaneous squamous cell carcinoma
PD-L1-i	Atezolizumab	NSCL, urothelial carcinoma
	Avelumab	Meckel cell carcinoma, urothelial carcinoma
	Durvalumab	Urothelial carcinoma, NSCLC
Combination of PD1-i and CTLA-4 i	Ipilimumab+ Nivolumab	Colorectal cancer (some subtypes), melanoma and RCC

PD-1-I, Programmed cell death ligand 1 inhibitor; CTLA-4 I, cytotoxic T lymphocyte antigen 4 inhibitor; HCC, hepatocellular carcinoma; ICI, immune checkpoint inhibitor; NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma; SCLC, small cell lung cancer [adapted after Zhou et al. (4) and Tajiri et al. (5)].